Novartis Debuts Rapidly Manufactured Autologous CAR-Ts

The company presented early data on two candidates at the ASH meeting that use a less than two-day manufacturing process, YTB323 in diffuse large B-cell lymphoma and PHE885 in multiple myeloma.

3d illustration of T cells or cancer cells
Novartis unveiled early data on its two next-generation CAR-Ts, YTB323 and PHE885 • Source: Shutterstock

Although it was the first mover in getting a chimeric antigen receptor T-cell (CAR-T) therapy approved, Novartis AG has somewhat fallen behind its peers in terms of number of cell therapies on the market and number of indications. Next-generation cell therapies like CAR-NKs and allogeneic CAR-Ts are coming into play as well. But the Swiss drug maker is looking to make its mark with a new autologous cell therapy technology that speeds manufacturing, and introduced early data on two of these candidates at the American Society of Hematology (ASH) annual meeting.

On 13 December, Novartis presented Phase I data at ASH for two autologous CAR-T therapy candidates, the CD19-targeting YTB323 in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer